Clinical Trial Detail

NCT ID NCT02890069
Title A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

lung non-small cell carcinoma

triple-receptor negative breast cancer

Therapies

LCL161 + Spartalizumab

Everolimus + Spartalizumab

Panobinostat + Spartalizumab

Age Groups: adult senior

No variant requirements are available.